Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.


SecuritySOYB / Teucrium Soybean Fund (88166A607)
Institutional Owners12
Institutional Shares283,199
Institutional Value$ 5,394,000 USD

Institutional Stock Ownership and Shareholders()

Teucrium Soybean Fund (NYSE:SOYB) has 12 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 283,199 shares. Largest shareholders include Mount Lucas Management LP, Susquehanna International Group, Llp, Jane Street Group, Llc, Wolverine Trading, Llc, Old Mission Capital, Llc, Flow Traders U.s. Llc, Crabel Capital Management, Llc, Cutler Group LP, Cutler Group LP, and UBS Group AG.
Teucrium Soybean Fund (NYSE:SOYB) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-14 13F-HR Virtu Financial LLC 10,492 0 -100.00 188 0 -100.00
2018-05-09 13F-HR Crabel Capital Management, Llc 11,514 219
2018-04-26 13F-HR SIMPLEX TRADING, LLC 1,859 1,556 -16.30 33 29 -12.12
2018-05-14 13F-HR FLOW TRADERS U.S. LLC 0 14,500 0 276
2018-05-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 1,000 1,000 0.00 18 19 5.56
2018-05-15 13F-HR WOLVERINE TRADING, LLC Call 0 18,400 0 351
2018-05-15 13F-HR UBS Group AG 855 3,017 252.87 15 57 280.00
2018-05-14 13F-HR MORGAN STANLEY 1,331 25
2018-05-11 13F-HR Cutler Group LP Call 0 3,700 0 2
2018-05-15 13F-HR JANE STREET GROUP, LLC 66,433 31,601 -52.43 1,199 602 -49.79
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 24,573 40,769 65.91 439 777 76.99
2018-05-15 13F-HR Mount Lucas Management LP 0 161,194 0 3,071
2017-02-15 13F-HR OLD MISSION CAPITAL, LLC 55,509 16,717 -69.88 722 319 -55.82
2018-05-11 13F-HR Cutler Group LP Put 0 11,000 0 2

Related Articles

CYTX: Cytori Therapeutics Analysis and Research Report

5h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

Related News Stories

4 Commodity ETFs Worst Hit by Ongoing Trade Turmoil

2018-07-12 zacks
Trade tensions, especially between the world’s two largest economies, have been taking a toll not only on the equity world but also on the commodity space. In fact, the escalating tit-for-tat tariff threats pushed the Bloomberg Commodity Index, which measures the returns on 25 raw materials down by 8.9% from the latest peak in late May. Notably, the index dropped as much as 2.80% on Jul 11, the most since 2014 after the United States threatened to impose 10% tariffs on further $200 billion in products imported from China, leading to further escalation in the U. (8-0)

China's $50B Tariff Backlash Puts These ETF Areas in Focus

2018-04-05 zacks
Trade war fears between the United States and China seem to be at its optimum level. President Trump first announced a pair of tariffs on steel and aluminum and then imposed about $50 billion in import duties on Chinese goods. In retaliation, China first announced $3 billion worth of tariffs on U.S. imports and most recently declared that it will levy tariffs on more than 100 American products, with a total trading value of over $50 billion. (62-0)

Soybean Update 4/5/18

2018-04-05 seekingalpha
Soybeans sold off heavily in the early morning hours of 4/4/18 following tariff announcements from China, but have recovered their losses.

China Tariffs Target US Farm Belt: Stocks and ETFs in Focus

2018-04-05 zacks
Finally, the dragon is ready to take on the eagle in the raging import tariff issue. Though the Asian country initially announced $3 billion worth of retaliatory tariffs on U.S. imports, it matched the tariff value (more than $50 billion) this week with the United States and declared that it will levy tariffs on more than 100 American products. The move came after the United States proposed $50 billion tariffs on 1,300 Chinese products (read: 8 Must-Watch ETFs if Trump Slams Tariffs on China by Friday). (68-0)

8 Must-Watch ETFs if Trump Slams Tariffs on China by Friday

2018-03-21 zacks
Global superpowers have started mulling over trade tensions starting March. The reason is Trump’s order to levy duties on steel and aluminum imports at the start of the month followed by his announcement to impose up to $60 billion in import duties on Chinese goods by Friday. Previously, Trump levied import tariffs on residential washing machines, as well as solar cells and modules too. (56-0)

CUSIP: 88166A607